Wcn26-5829 Efficacy and Safety of Finerenone and Empagliflozin in Patients With Initial Decline in Estimated Glomerular Filtration Rate: A Confidence Trial Prespecified Analysis

Serious adverse events were reported in 8.5%, 10.5%, and 3.8%, respectively.TEAEs leading to treatment discontinuation occurred in 0.9%, 3.8%, and 1.0%.The incidence of steroid-specific side effects (e.g., moon face, buffalo hump) was low and generally mild.No deaths were reported. Conclusion:Nine months of treatment with targeted-release HR19042 capsules produced a clinically meaningful reduction in proteinuria and slowed eGFR decline compared with placebo, indicating a potential disease-modifying effect in patients with IgA nephropathy.HR19042 was generally well tolerated, with a safety profile consistent with locally acting oral budesonide.I have potential conflict of interest to disclose.Rong Huang and Su Zhang report being employed by Jiangsu Hengrui Pharmaceuticals.